The study highlighted a few differences between "real-world" patients and those in trials:
: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can:
: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression).
: Finding ways to help patients manage side effects so they can stay on the therapy longer.
The study highlighted a few differences between "real-world" patients and those in trials:
: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can: (616 KB)
: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). The study highlighted a few differences between "real-world"
: Finding ways to help patients manage side effects so they can stay on the therapy longer. I can: : Interestingly